Treatment with surgery and chemotherapy in a 42-year-old man with primary cardiac angiosarcoma resulted in disease progression and death after 3 months, confirming its fatal prognosis.
Case Report (n=1)
No
This case report highlights the highly fatal nature and rapid progression of primary cardiac angiosarcoma despite surgical and chemotherapeutic interventions.
A 42-year-old man with a cardiac tamponade underwent an urgent pericardiotomy that showed tumoral tissue, covering the surface of the right atrium. The tumor was then partially excised, and the histological examination revealed the presence of a moderately-differentiated angiosarcoma. The patient was then referred to the oncology unit and scheduled for a chemotherapy schedule including Epirubicin (60 mg/m(2), on days 1 and 2) plus Ifosfamide (2000 mg/m(2), on days 1 to 3) and Uromitexan (2000 mg/m(2) at hours 0, 4, 8 after IFO). All drugs were administered every three weeks. After two cycles, a restaging work-up revealed a partial remission. The treatment was continued for another two cycles. A new evaluation by cardiac MRI evidenced a local and distant (lung) progression of disease. The patient died after three months. This paper confirms that cardiac angiosarcoma is a fatal disease, and the prognosis is usually 6-11 months from time of diagnosis.
Antonuzzo et al. (Thu,) conducted a case report in Primary cardiac angiosarcoma (n=1). Surgery and chemotherapy (Epirubicin, Ifosfamide, Uromitexan) was evaluated on Disease progression and survival. Treatment with surgery and chemotherapy in a 42-year-old man with primary cardiac angiosarcoma resulted in disease progression and death after 3 months, confirming its fatal prognosis.